Spirochetes Bhlp29.7 antibody and antigen (recombinant protein)

Diagnostic anti-Spirochetes Bhlp29.7 antibodies pairs and antigen for animal health (animal Swine/Porcine/Pig infectious disease dysentery) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Target products collectionGo to Swine/Porcine/Pig disease testing products collection >>


Product information

Catalog No. Description US $ Price (per mg)
GMP-VT-P096-Tg001-Ag01 Recombinant Spirochetes Bhlp29.7 protein $3090.00
GMP-VT-P096-Tg001-Ab01 Anti-Spirochetes Bhlp29.7 mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P096-Tg001-Ab02 Anti-Spirochetes Bhlp29.7 mouse monoclonal antibody (mAb) $3090.00
GMP-VT-P096-Tg001-Ab03 Anti-Spirochetes Bhlp29.7 human monoclonal antibody (mAb) $3090.00
GMP-VT-P096-Tg001-Ab04 Anti-Spirochetes Bhlp29.7 human monoclonal antibody (mAb) $3090.00

Size: 1mg | 10mg | 100mg



Product Description

Cat No. GMP-VT-P096-Tg001-Ag01
Product Name Recombinant Spirochetes Bhlp29.7 protein
Pathogen Spirochetes
Expression platform E.coli
Isotypes Recombinant Antigen
Bioactivity validation Anti-Spirochetes Bhlp29.7 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Spirochetes level test of animal Swine/Porcine/Pig infectious disease with dysentery.
Tag His
Product description Recombinant Spirochetes Bhlp29.7 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P096-Tg001-Ab01,GMP-VT-P096-Tg001-Ab02
Pathogen Spirochetes
Product Name Anti-Spirochetes Bhlp29.7 mouse monoclonal antibody (mAb)
Expression platform CHO
Isotypes Mouse IgG
Bioactivity validation Recombinant Spirochetes Bhlp29.7 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Spirochetes antibodies in Spirochetes level test of animal Swine/Porcine/Pig infectious disease with dysentery.
Product description Anti-Spirochetes Bhlp29.7 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Spirochetes antibodies.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Cat No. GMP-VT-P096-Tg001-Ab03,GMP-VT-P096-Tg001-Ab04
Pathogen Spirochetes
Product Name Anti-Spirochetes Bhlp29.7 human monoclonal antibody (mAb)
Expression platform CHO
Isotypes Human lgG1
Bioactivity validation Recombinant Spirochetes Bhlp29.7 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Spirochetes antibodies in Spirochetes level test of animal Swine/Porcine/Pig infectious disease with dysentery.
Product description Anti-Spirochetes Bhlp29.7 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity Purity: ≥95% (SDS-PAGE)
Application Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Pathogen Information


    At that time, the world was undergoing significant changes, both socially and technologically. The ongoing COVID-19 pandemic had already transformed various aspects of our daily lives, prompting widespread adoption of remote work, online education, and digital communication tools. Despite the challenges posed by the pandemic, scientific communities and pharmaceutical companies were actively engaged in developing vaccines to combat the virus. The emergence of several effective vaccines, such as those developed by Pfizer-BioNTech, Moderna, and AstraZeneca, offered hope for controlling the spread of the virus and returning to a semblance of normalcy.

    In terms of technological advancements, artificial intelligence and machine learning were rapidly evolving fields, with applications across various industries, including healthcare, finance, and customer service. Companies were increasingly investing in AI-driven solutions to streamline their operations, enhance customer experiences, and gain valuable insights from data analysis. Additionally, the rise of automation and robotics was reshaping the job market, leading to discussions about the potential impact on employment and the need for upskilling and reskilling programs.

    The field of renewable energy was also experiencing significant growth, driven by a global push for sustainability and reduced carbon emissions. Solar and wind power, in particular, were becoming increasingly cost-effective and accessible, leading to their widespread adoption in many regions. Governments and organizations were implementing policies and initiatives to encourage the transition to clean energy sources and combat climate change.

    Furthermore, the realm of space exploration and technology was witnessing notable advancements. Private companies such as SpaceX, Blue Origin, and Virgin Galactic were actively involved in developing reusable rocket technology and aiming to make space travel more accessible to the public. Meanwhile, international space agencies were collaborating on missions to explore Mars, the Moon, and other celestial bodies, seeking to expand our understanding of the universe and the potential for human colonization beyond Earth.

    These developments, along with numerous other ongoing global trends, were shaping the world in 2021, emphasizing the importance of innovation, sustainability, and adaptability in navigating the challenges and opportunities of the modern era.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.